keyword
https://read.qxmd.com/read/38531803/analysis-and-investigation-of-bioinformatics-and-epigenetics-reveal-the-underlying-mechanisms-by-which-flot2-modulates-the-progression-of-diffuse-large-b-cell-lymphoma
#1
JOURNAL ARTICLE
Yujing Zhang, Yao Chen, Qiang Guo, Ying Zhang, Aichun Liu
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) poses a significant threat to the quality of life for people worldwide. Regrettably, effective treatment strategies for this disease remain elusive in clinical practice due to the unclear understanding of its molecular mechanisms. Therefore, this study was devised to address these issues and identify novel diagnostic, therapeutic, and prognostic biomarkers for DLBCL. METHODS: Gene expression and clinical data for DLBCL patients were retrieved from The Cancer Genome Atlas (TCGA) database, and relevant clinical data, tumor mutational burden (TMB), and gene expression levels were extracted...
March 2024: Discovery Medicine
https://read.qxmd.com/read/38519055/molecular-assessment-of-intratumoral-immune-cell-subsets-and-potential-mechanisms-of-resistance-to-odronextamab-a-cd20%C3%A3-cd3-bispecific-antibody-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma
#2
JOURNAL ARTICLE
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Max S Topp, Rajat Bannerji, Johannes Duell, Ranjana H Advani, Dina M Flink, Aafia Chaudhry, Gavin Thurston, Srikanth R Ambati, Vladimir Jankovic
BACKGROUND: Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via T-cell-mediated cytotoxicity independent of T-cell/major histocompatibility complex interaction. Phase I results in patients with R/R B-NHL demonstrated that odronextamab monotherapy could achieve deep and durable responses with a generally manageable safety profile (ELM-1; NCT02290951)...
March 21, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38517810/biomarkers-and-coptis-chinensis-activity-for-rituximab-resistant-diffuse-large-b-cell-lymphoma-combination-of-bioinformatics-analysis-network-pharmacology-and-molecular-docking
#3
JOURNAL ARTICLE
Qiuling Zhao, Shengqiang Huang, Lin Yang, Ting Chen, Xiuliang Qiu, Ruyi Huang, Liangliang Dong, Wenbin Liu
BACKGROUND: Rituximab resistance is one of the great challenges in the treatment of diffuse large B-cell lymphoma (DLBCL), but relevant biomarkers and signalling pathways remain to be identified. Coptis chinensis and its active ingredients have antitumour effects; thus, the potential bioactive compounds and mechanisms through which Coptis chinensis acts against rituximab-resistant DLBCL are worth exploring. OBJECTIVE: To elucidate the core genes involved in rituximab-resistant DLBCL and the potential therapeutic targets of candidate monomers of Coptis chinensis...
February 29, 2024: Technology and Health Care: Official Journal of the European Society for Engineering and Medicine
https://read.qxmd.com/read/38517778/identification-of-a-prognostic-signature-based-on-five-ferroptosis-related-genes-for-diffuse-large-b-cell-lymphoma
#4
JOURNAL ARTICLE
Wuping Li, Ruizhe Yao, Nasha Yu, Weiming Zhang
BACKGROUND: Therapies for diffuse large B-cell lymphoma (DLBCL) are limited due to the diverse gene expression profiles and complicated immune microenvironments, making it an aggressive lymphoma. Beyond this, researches have shown that ferroptosis contributes to tumorigenesis, progression, and metastasis. We thus are interested to dissect the connection between ferroptosis and disease status of DLBCL. We aim at generating a valuable prognosis gene signature for predicting the status of patients of DLBCL, with focus on ferroptosis-related genes (FRGs)...
March 7, 2024: Cancer Biomarkers: Section A of Disease Markers
https://read.qxmd.com/read/38516380/il-2-cd25-axis-mediates-cellular-networks-promoting-the-growth-of-cd25-acute-myeloid-leukemia-cells
#5
JOURNAL ARTICLE
Kazunori Nakase, Kenkichi Kita
Although the expression of interleukin-2 receptor α-chain (IL-2Rα, CD25) has been provided prognostic significance independent of known biomarkers in acute myeloid leukemia (AML), the functional role of CD25 molecule remains unknown. Since IL-2 can be trans-presented via CD25 to another cell, CD25+ AML cells may deliver environmental IL-2 to surrounding immune cells to produce myeloid growth factors for their proliferation. We hypothesize that cellular interactions via IL-2/CD25 axis in the bone marrow microenvironment contributes to the growth advantage of these AML cells and affects the clinical outcome of those AML patients...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38509948/combination-of-theoretical-analysis-and-experiments-exploring-the-role-of-pla2g7-in-human-cancers-including-renal-cancer
#6
JOURNAL ARTICLE
Jun Xie, Li Zhu, Xutao Yang, Fengfei Yu, Bingfu Fan, Yibo Wu, Zonglang Zhou, Weiqiang Lin, Yi Yang
BACKGROUND: The pivotal role of phospholipase A2 group VII ( PLA2G7 ) has been identified in specific human cancers, such as prostate cancer, diffuse large B cell lymphoma, and melanoma. Given PLA2G7 's significant involvement in established tumors, exploring its role in other cancers is highly relevant. METHODS: In this study, we acquired and analyzed data from The Cancer Genome Atlas database, the UCSC XENA website, and other online platforms including Gene Set Cancer Analysis, cBioPortal, Tumor Immune Estimation Resource, and TISIDB to investigate PLA2G7 's role in human cancers, including renal cancer...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38508880/long-term-follow-up-of-the-combination-of-ofatumumab-high-dose-methylprednisolone-and-lenalidomide-for-untreated-chronic-lymphocytic-leukemia-with-biomarker-analysis
#7
JOURNAL ARTICLE
Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero-Palma, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
BACKGROUND: Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- naïve (TN) CLL/SLL patients. METHODS: This was a single-center, phase 2 study of high-dose methylprednisolone (HDMP) and ofatumumab with lenalidomide and ofatumumab consolidative therapy for all comers with TN CLL/SLL...
February 13, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38506241/clinicopathological-features-of-adult-t-cell-leukemia-lymphoma-with-t-follicular-helper-phenotype
#8
JOURNAL ARTICLE
Reiji Muto, Hiroaki Miyoshi, Kazutaka Nakashima, Mai Takeuchi, Makoto Hamasaki, Koichi Ohshima
AIMS: T-follicular helper (TFH) cells are effector T-cells that are crucial for B-cell selection and differentiation. T-cell lymphomas derived from TFH cells have distinct characteristics. Additionally, in the World Health Organization (WHO) classification 5th edition, three lymphomas were introduced as independent disease entities with TFH cell origin. We aimed to investigate the clinicopathological features of adult T-cell leukemia/lymphoma (ATLL) with a TFH phenotype (TFHP). METHODS AND RESULTS: We performed TFH immunohistochemistry analysis of five biomarkers for the biopsy specimen, with TFHP being indicated by a positive result for more than two markers...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38504519/high-multiplex-single-cell-imaging-analysis-reveals-tumor-immune-contexture-associated-with-clinical-outcomes-after-car-t-cell-therapy
#9
JOURNAL ARTICLE
Jin Jin, Li Lin, Jiao Meng, Lijun Jiang, Man Zhang, Yuekun Fang, Wanying Liu, Xiangke Xin, Xiaolu Long, Dong Kuang, Xilai Ding, Miao Zheng, Yicheng Zhang, Yi Xiao, Liting Chen
Chimeric antigen receptor (CAR) T-cell therapy has made great progress in treating lymphoma, yet patient outcomes still vary greatly. The lymphoma microenvironment may be an important factor in the efficacy of CAR T therapy. In this study, we designed a highly multiplexed imaging mass cytometry (IMC) panel to simultaneously quantify 31 biomarkers from 13 patients with relapsed/refractory DLBCL who received CAR19/22 T-cell therapy. A total of twenty sections were sampled before CAR T-cell infusion or after infusion when relapse occurred...
March 18, 2024: Molecular Therapy
https://read.qxmd.com/read/38496687/pd-l1-mrna-derived-from-tumor-educated-platelets-as-a-potential-immunotherapy-biomarker-in-non-small-cell-lung-cancer
#10
JOURNAL ARTICLE
Zhihuang Hu, Na Wang, Yao Zhang, Daoyun Zhang, Si Sun, Hui Yu, Ying Lin, Xinmin Zhao, Huijie Wang, Xianghua Wu, Yoshinobu Ichiki, Satoshi Watanabe, Ziying Gong, Jianhua Chang, Jialei Wang
BACKGROUND: To date, the role of programmed death ligand-1 (PD-L1) messenger RNA (mRNA) derived from tumor-educated platelets (TEPs) has not been well investigated in patients with advanced non-small cell lung cancer (NSCLC). A few reports have examined whether mRNA in TEPs can predict the clinical responses of patients with advanced NSCLC following immunotherapy. This study aimed to identify novel biomarkers to improve the clinical benefits and outcomes of NSCLC patients. METHODS: Advanced NSCLC patients receiving a combination of immunotherapy and chemotherapy, or immunotherapy alone as a first- or second-line treatment at the Fudan University Shanghai Cancer Center were enrolled in this study...
February 29, 2024: Translational Lung Cancer Research
https://read.qxmd.com/read/38494279/paraneoplastic-movement-disorders
#11
REVIEW
Andrew McKeon, Jennifer Tracy
Paraneoplastic movement disorders are diverse autoimmune neurological illnesses occurring in the context of systemic cancer, either in isolation or as part of a multifocal neurological disease. Movement phenomena may be ataxic, hypokinetic (parkinsonian), or hyperkinetic (myoclonus, chorea, or other dyskinetic disorders). Some disorders mimic neurodegenerative or hereditary illnesses. The subacute onset and coexisting nonclassic features of paraneoplastic disorders aid distinction. Paraneoplastic autoantibodies provide further information regarding differentiating cancer association, disease course, and treatment responses...
2024: Handbook of Clinical Neurology
https://read.qxmd.com/read/38487720/case-report-from-sequence-to-solution-tailoring-treatment-for-transformed-follicular-lymphoma-dlbcl-through-next-generation-sequencing-study
#12
Antonin Bouroumeau, Sarah Perdikis-Prati, Noémie Lang
Immune checkpoint blockade (ICB) has indeed transformed the outlook for many advanced-stage solid tumors, yet its effectiveness in hematological malignancies has been particularly limited, with success predominantly demonstrated in classical Hodgkin lymphoma (cHL) and immune-privilege subtypes of non-Hodgkin lymphoma (NHL). In this report, we present an impactful case of a 71-year-old man grappling with refractory follicular lymphoma (rFL) that had progressed to a high-grade lymphoma, leaving no conventional treatment options on the table...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38482423/-nf2-is-a-candidate-diagnosis-prognostic-and-immunotherapeutic-biomarker-a-systematic-pan-cancer-analysis
#13
JOURNAL ARTICLE
Honglu Zhang, Jiyong Liu
BACKGROUND: Neurofibromin 2 ( NF2 ) regulates diverse cellular events such as transcription, translation, ubiquitination, and micro-RNA biosynthesis. Previous evidence revealed that aberrant expression of NF2 contributes to tumorigenesis in mesothelioma, meningioma, and breast cancer. However, there is no comprehensive pan-cancer analysis to explore NF2 's function in cancer diagnosis, prognosis, and immunological prediction. METHODS: By extensive use of data profiles from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) project, Cancer Cell Line Encyclopedia (CCLE), CIBERSORT, Human Protein Atlas (HPA), and cBioPortal, we employed various bioinformatics methods to explore the role of NF2 in pan-cancer, including analyzing the association between NF2 and tumor diagnosis, prognosis, immune cell infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI)...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38476335/clinical-predictors-of-response-to-single%C3%A2-agent-immune-checkpoint-inhibitors-in-chemotherapy%C3%A2-pretreated-non%C3%A2-small-cell-lung-cancer
#14
JOURNAL ARTICLE
Aram A Musaelyan, Fedor V Moiseyenko, Tancholpon E Emileva, Ani P Oganesyan, Karina A Oganyan, Magaripa A Urtenova, Svetlana V Odintsova, Ivan V Chistyakov, Alexey M Degtyarev, Andrey L Akopov, Evgeny N Imyanitov, Sergey V Orlov
Single-agent immune checkpoint inhibitors (ICIs) are the standard option for chemotherapy-pretreated metastatic non-small cell lung cancer (NSCLC), however only a subset of patients responds to this treatment. The present study aimed at the development of a tool for personalized prediction of the efficacy of ICIs. The study included 181 epidermal growth factor receptor/anaplastic lymphoma kinase-negative patients with metastatic NSCLC receiving single-agent ICI in the second or later line of therapy. For the comparison, a total of 63 metastatic patients with NSCLC treated by chemotherapy were also analyzed...
April 2024: Molecular and Clinical Oncology
https://read.qxmd.com/read/38474108/serum-soluble-cd163-levels-as-a-prognostic-biomarker-in-patients-with-diffuse-large-b-cell-lymphoma-treated-with-chemoimmunotherapy
#15
JOURNAL ARTICLE
Aspasia Koudouna, Annita Ioanna Gkioka, Alexandros Gkiokas, Thomai M Tryfou, Mavra Papadatou, Alexandros Alexandropoulos, Vassiliki Bartzi, Nikolitsa Kafasi, Marie-Christine Kyrtsonis
The majority of patients with Diffuse Large B-cell Lymphoma (DLBCL) will respond to first-line treatment and be cured. However, the disease is heterogeneous, and biomarkers able to discriminate patients with suboptimal prognosis are needed. M2 CD163-positive tumor-associated macrophages (TAMs) were shown to be implicated in DLBCL disease activity regulation. Serum-soluble CD163 (sCD163) functions as a scavenger receptor for haptoglobin-hemoglobin complexes and is mostly expressed by monocytes and macrophages...
March 1, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473401/the-neutrophil-to-lymphocyte-ratio-as-a-biomarker-in-cutaneous-oncology-a-systematic-review-of-evidence-beyond-malignant-melanoma
#16
REVIEW
Konstantinos Seretis, Konstantinos Sfaelos, Elena Boptsi, Georgios Gaitanis, Ioannis D Bassukas
With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melanoma, to support their potential use in the prognosis but also in the assessment of therapeutic strategies for the specific category of skin disorders...
March 4, 2024: Cancers
https://read.qxmd.com/read/38473222/jak-inhibitors-in-cutaneous-t-cell-lymphoma-friend-or-foe-a-systematic-review-of-the-published-literature
#17
REVIEW
Seyed Mohammad Vahabi, Saeed Bahramian, Farzad Esmaeili, Bardia Danaei, Yasamin Kalantari, Patrick Fazeli, Sara Sadeghi, Nima Hajizadeh, Chalid Assaf, Ifa Etesami
Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for CTCL treatment. This study is a systematic review aiming to investigate the role of JAK inhibitors in the treatment of CTCL, including their efficacy and safety. Out of 438 initially searched articles, we present 13 eligible ones...
February 21, 2024: Cancers
https://read.qxmd.com/read/38469299/cd8-nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma
#18
JOURNAL ARTICLE
Lourdes Hontecillas-Prieto, Daniel J García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino
BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38468047/computational-fractal-based-analysis-of-mr-susceptibility-weighted-imaging-swi-in-neuro-oncology-and-neurotraumatology
#19
JOURNAL ARTICLE
Antonio Di Ieva
Susceptibility-weighted imaging (SWI) is a magnetic resonance imaging (MRI) technique able to depict the magnetic susceptibility produced by different substances, such as deoxyhemoglobin, calcium, and iron. The main application of SWI in clinical neuroimaging is detecting microbleedings and venous vasculature. Quantitative analyses of SWI have been developed over the last few years, aimed to offer new parameters, which could be used as neuroimaging biomarkers. Each technique has shown pros and cons, but no gold standard exists yet...
2024: Advances in Neurobiology
https://read.qxmd.com/read/38466231/uncovering-protac-sensitivity-and-efficacy-by-multidimensional-proteome-profiling-a-case-for-stat3
#20
JOURNAL ARTICLE
Yuying Suo, Daohai Du, Chao Chen, Hongwen Zhu, Xiongjun Wang, Nixue Song, Dayun Lu, Yaxi Yang, Jiacheng Li, Jun Wang, Zhongyuan Luo, Bing Zhou, Cheng Luo, Hu Zhou
Proteolysis-targeting chimera (PROTAC) is a powerful technology that can effectively trigger the degradation of target proteins. The intricate interplay among various factors leads to a heterogeneous drug response, bringing about significant challenges in comprehending drug mechanisms. Our study applied data-independent acquisition-based mass spectrometry to multidimensional proteome profiling of PROTAC (DIA-MPP) to uncover the efficacy and sensitivity of the PROTAC compound. We profiled the signal transducer and activator of transcription 3 (STAT3) PROTAC degrader in six leukemia and lymphoma cell lines under multiple conditions, demonstrating the pharmacodynamic properties and downstream biological responses...
March 11, 2024: Journal of Medicinal Chemistry
keyword
keyword
7294
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.